ERBB2 and neoplasm: However, no significant associations were observed between CLEC-2 levels and age (< 50 vs. ≥ 50), lymph node metastasis (N2+N3 vs. N0+N1), Ki67 status (< 14% vs. ≥ 14%), HER2/ER/PR status (positive vs. negative), or molecular tumor subtype (luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-enriched, or triple-negative), as all p-values were > 0.05 (Table 2).